Literature DB >> 16856208

Alternating vector immunizations encoding pre-erythrocytic malaria antigens enhance memory responses in a malaria endemic area.

Philip Bejon1, Oscar K Kai, Jedidah Mwacharo, Sheila Keating, Trudie Lang, Sarah C Gilbert, Norbert Peshu, Kevin Marsh, Adrian V S Hill.   

Abstract

A heterologous prime-boost strategy has been developed to potently induce T cell responses to pre-erythrocytic malaria antigens. Efficacy in the field is likely to depend on both peak immunogenicity and the durability of responses. To improve both immunogenicity and durability of responses, 54 adult males from a malaria endemic area were immunized with different vaccination regimens, systematically varying antigenic insert and the number and sequence of component vaccinations. The component vaccinations were recombinant attenuated viruses, either fowlpox (FP) 9 or modified vaccinia virus Ankara (MVA). These were recombinant for either of two pre-erythrocytic malaria antigens (multiple epitope-thrombospondin-related adhesion protein, ME-TRAP, or circumsporozoite antigen (CS). ELISPOT assays were used to measure the effector and resting memory T cell responses. Sequence, antigen insert and number of vaccinations influenced immunogenicity, but the novel alternating vector immunizations generated the largest resting memory T cell populations. Effector responses were maintained at 84% of the peak response after 270 days. This durability of response is unprecedented. Classical prime-boost vaccination responses were at 5% of the peak after 270 days. Vaccines administered by heterologous prime-boost regimes are being developed for diverse pathogens and cancer. These data suggest these vaccines should also be administered by alternating vector regimens in clinical development.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16856208     DOI: 10.1002/eji.200636187

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  9 in total

Review 1.  Viral vector vaccines make memory T cells against malaria.

Authors:  Arturo Reyes-Sandoval; John T Harty; Stephen M Todryk
Journal:  Immunology       Date:  2007-06       Impact factor: 7.397

2.  A phase I trial of preventive HIV vaccination with heterologous poxviral-vectors containing matching HIV-1 inserts in healthy HIV-uninfected subjects.

Authors:  Michael C Keefer; Sharon E Frey; Marnie Elizaga; Barbara Metch; Stephen C De Rosa; Paulo F Barroso; Georgia Tomaras; Massimo Cardinali; Paul Goepfert; Artur Kalichman; Valérie Philippon; M Juliana McElrath; Xia Jin; Guido Ferrari; Olivier D Defawe; Gail P Mazzara; David Montefiori; Michael Pensiero; Dennis L Panicali; Lawrence Corey
Journal:  Vaccine       Date:  2011-01-07       Impact factor: 3.641

3.  Memory CD8 T cell responses exceeding a large but definable threshold provide long-term immunity to malaria.

Authors:  Nathan W Schmidt; Rebecca L Podyminogin; Noah S Butler; Vladimir P Badovinac; Brad J Tucker; Keith S Bahjat; Peter Lauer; Arturo Reyes-Sandoval; Claire L Hutchings; Anne C Moore; Sarah C Gilbert; Adrian V Hill; Lyric C Bartholomay; John T Harty
Journal:  Proc Natl Acad Sci U S A       Date:  2008-09-09       Impact factor: 11.205

4.  Preclinical assessment of the receptor-binding domain of Plasmodium vivax Duffy-binding protein as a vaccine candidate in rhesus macaques.

Authors:  A Moreno; I Caro-Aguilar; S S Yazdani; A R Shakri; S Lapp; E Strobert; H McClure; C E Chitnis; M R Galinski
Journal:  Vaccine       Date:  2008-06-23       Impact factor: 3.641

5.  The induction and persistence of T cell IFN-gamma responses after vaccination or natural exposure is suppressed by Plasmodium falciparum.

Authors:  Philip Bejon; Jedidah Mwacharo; Oscar Kai; Stephen Todryk; Sheila Keating; Brett Lowe; Trudie Lang; Tabitha W Mwangi; Sarah C Gilbert; Norbert Peshu; Kevin Marsh; Adrian V S Hill
Journal:  J Immunol       Date:  2007-09-15       Impact factor: 5.422

6.  Early gamma interferon and interleukin-2 responses to vaccination predict the late resting memory in malaria-naïve and malaria-exposed individuals.

Authors:  Philip Bejon; Sheila Keating; Jedidah Mwacharo; Oscar K Kai; Susanna Dunachie; Michael Walther; Tamara Berthoud; Trudie Lang; Judy Epstein; Daniel Carucci; Philippe Moris; Joe Cohen; Sarah C Gilbert; Norbert Peshu; Kevin Marsh; Adrian V S Hill
Journal:  Infect Immun       Date:  2006-09-11       Impact factor: 3.441

Review 7.  A review of malaria vaccine clinical projects based on the WHO rainbow table.

Authors:  Lauren Schwartz; Graham V Brown; Blaise Genton; Vasee S Moorthy
Journal:  Malar J       Date:  2012-01-09       Impact factor: 2.979

8.  A phase 2b randomised trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.

Authors:  Philip Bejon; Jedidah Mwacharo; Oscar Kai; Tabitha Mwangi; Paul Milligan; Stephen Todryk; Sheila Keating; Trudie Lang; Brett Lowe; Caroline Gikonyo; Catherine Molyneux; Greg Fegan; Sarah C Gilbert; Norbert Peshu; Kevin Marsh; Adrian V S Hill
Journal:  PLoS Clin Trials       Date:  2006-10-20

9.  Translating the immunogenicity of prime-boost immunization with ChAd63 and MVA ME-TRAP from malaria naive to malaria-endemic populations.

Authors:  Domtila Kimani; Ya Jankey Jagne; Momodou Cox; Eva Kimani; Carly M Bliss; Evelyn Gitau; Caroline Ogwang; Muhammed O Afolabi; Georgina Bowyer; Katharine A Collins; Nick Edwards; Susanne H Hodgson; Christopher J A Duncan; Alexandra J Spencer; Miguel G Knight; Abdoulie Drammeh; Nicholas A Anagnostou; Eleanor Berrie; Sarah Moyle; Sarah C Gilbert; Peninah Soipei; Joseph Okebe; Stefano Colloca; Riccardo Cortese; Nicola K Viebig; Rachel Roberts; Alison M Lawrie; Alfredo Nicosia; Egeruan B Imoukhuede; Philip Bejon; Roma Chilengi; Kalifa Bojang; Katie L Flanagan; Adrian V S Hill; Britta C Urban; Katie J Ewer
Journal:  Mol Ther       Date:  2014-06-16       Impact factor: 11.454

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.